Business Wire

CEA & Dawex Create a Joint Research & Development Laboratory to Advance Innovation in Industries

Share

Dawex and CEA today announced that they have signed a partnership agreement to create a joint Research & Development Laboratory. Aiming at conceiving and developing technological solutions to catalyze truly impactful innovations in the field of data ecosystem, the collaboration between the CEA and Dawex will feed responses to global industry challenges to shape a more sustainable & resilient future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528953935/en/

The creation of secure, trusted and interoperable data ecosystems and data spaces has become crucial in fostering trusted artificial intelligence and realizing a sustainable and digital society. Data exchange and data circulation are at the forefront in boosting transformative solutions such as Generative AI, while pushing the boundaries of innovation thanks to Privacy Enhancing Technologies integration —ultimately making such disruptive technologies accessible to customers.

Since its inception, Dawex has been investing in Research & Development, in order to bring the perfect conditions for secure, trustworthy, sovereign and compliant data exchange. Dawex will bring to this collaboration its extensive and proven expertise in secure data exchange, data governance, interoperability, standards & norms. Through active engagements in developing the most advanced data exchange solutions and contributing to regulations, norms & de facto standards, Dawex has been demonstrating its leadership as a strategic market player, notably by powering the largest number of European data spaces.

The CEA participates in accelerating industry transformation with programs on the factory of the future, digital twins, artificial intelligence, and digital trust. It ultimately contributes to building a powerful innovation ecosystem guided by the values of social and environmental responsibility.

“Innovation and Research have been in Dawex DNA since Day-1. We are committed to advancing data exchange matters and address forward looking data challenges, delivering the most sophisticated data exchange technology” said Fabrice Tocco, co-CEO at Dawex. “We are extremely happy to collaborate with the CEA and co-innovate to bring the next-generation innovations that will transform data exchange,” concluded Mr Tocco.

”Data exchange plays a major role in the industry transformation that France and Europe are facing today. This leads CEA to partner with Dawex as a leading company in the field of data exchange and data ecosystems”, declared Alexandre Bounouh, CEO of CEA List institute. “Creating together a common R&D laboratory will enable us to bring thorough and trusted digital solutions to the industry with one objective in mind: to accelerate transitions and among them energy & climate ones. We are delighted to pursue this ambition with Dawex”.

About Dawex

Dawex is the leader in Data Exchange solutions to distribute or share data products, with trust, for any business case, in compliance with data regulations. With Dawex Data Exchange technology, organizations create data ecosystems and data spaces such as Corporate Data Hubs, Industry Data Hubs and Data Marketplaces to address economic, environmental and decarbonation challenges. At the invitation of the United Nations, Dawex joins the Data expert group of the United Nations Environment Program. Awarded Technology Pioneer by the World Economic Forum, Dawex is also the initiator of an international standardization program on Trusted Data Transaction. Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.

About CEA

The CEA is a major research organisation working in the best interests of the French State, its economy and citizens. Thanks to its strong roots in fundamental research, it is able to provide tangible solutions to meet their needs in four key fields: low-carbon energy, digital technologies, technologies for medicine of the future, defence and national security.
As the world's leading innovator among public research organisations (Clarivate 2024), the CEA acts as a catalyst and accelerator of innovation for French industry. It helps businesses in all sectors be more competitive, creating high-performance products that stand out from the crowd and developing trail-blazing solutions that lead to changes in society. The CEA deploys this dynamic in all regions of France aiding local partners to innovate themselves, thus helping to create sustainable value and jobs nationwide, tailored to meet actual industry needs. At the same time, it supports the development of its 250 start-ups, agile vectors for transferring the disruptive technology and knowledge developed at CEA laboratories to industry. More information: https://www.cea.fr/english

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact: Isabelle Joulot, Vice President Communications & Marketing, press@dawex.com

Press Contact: Guilhem Boyer, Press officer, guilhem.boyer@cea.fr, +33 6 73 41 42 45

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 05:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

PMC Biogenix Announces Expansion and Restructure22.6.2024 00:00:00 EEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 23:58:00 EEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 23:30:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 23:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye